Purpose of review: This review will summarize the most current literature on the clinical impact, epidemiology, risk factors, screening recommendations, predictors of outcomes, and treatment options in patients with pulmonary arterial hypertension PAH associated with systemic sclerosis SSc. Many risk factors and predictors of outcomes have been identified in patients with SSc including clinical, hemodynamic, and laboratory parameters. Despite many available treatment options for PAH, prognosis remains poor. Awareness of risk factors, early detection, and up-front combination treatment are important considerations in SSc-PAH and may lead to improved outcomes.
Takayasu arteritis as a cause of arterial hypertension. Case report and literature review
Literature Review Related Literature On Hypertension | Bartleby
Background: Pulmonary arterial hypertension PAH is a severe chronic condition associated with poor quality of life and high risks of mortality and hospitalisation. The utilisation of novel diagnostic technologies has improved survival rates although the effectiveness of Electronic Health eHealth interventions in patients with a chronic cardiopulmonary disease remains controversial. As the effectiveness of eHealth can be established by specific evaluation for different chronic health conditions, the aim of this study was to explore and summarise the utilisation of eHealth in PAH. No limitations in terms of study design or date of publication were imposed. Results: 18 studies 6 peer-reviewed journal papers and 12 conference papers were identified. Seven studies addressed the accuracy, safety or reliability of eHealth technologies such as intra-arterial haemodynamic monitoring of the pulmonary artery pressure, self-administered 6-Minute walk test App, computerised step-pulse oximeter and ambulatory impedance cardiography.
Literature Review Related Literature On Hypertension
Background: Despite the development of advanced therapies for pulmonary arterial hypertension, pregnancy remains contraindicated in these patients owing to high maternal and fetal morbidity and mortality. Limited data exist regarding pregnancy management and outcome in this unique patient population. We describe a series of pregnant patients diagnosed as having pulmonary arterial hypertension before or during pregnancy who delivered at a tertiary center with a comprehensive and established pulmonary vascular disease program.
US Pharm. Pulmonary arterial hypertension PAH is a progressive disease that affects the small pulmonary arteries and is characterized by vasoconstriction, medial hypertrophy, cell proliferation and fibrosis, complex lesions plexiform lesions , and thrombosis in situ. Right-heart catheterization should always be performed to confirm the diagnosis of PAH and chronic thromboembolic PH.